In Q2 2023, Deep Track Capital held 42 positions worth $1.9B. They initiated 10 new positions and exited 6. Their largest holding was JAZZ ($155.0M). Portfolio value grew +7.9% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q2 2023?
Deep Track Capital held 42 biotech stocks in their 13F portfolio in Q2 2023. Their top positions include JAZZ, INSM, IONS, TVTX, GPCR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q2 2023?
Deep Track Capital's tracked biotech portfolio was worth $1.9B across 42 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q2 2023?
Deep Track Capital initiated 10 new positions in Q2 2023, including GH, EDIT, ANIP, AXSM, ZURA and 5 more. They also increased 10 existing positions.
What did Deep Track Capital sell in Q2 2023?
Deep Track Capital fully exited 6 positions in Q2 2023, including QURE, NKTX, EXEL, DCPH, BIIB and 1 more. They also trimmed 9 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capital portfolio →